Canada markets close in 3 hours 43 minutes

AbbVie Inc. (ABBV)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
108.57+1.50 (+1.40%)
As of 12:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close107.07
Open107.13
Bid108.56 x 800
Ask108.59 x 900
Day's Range107.05 - 108.61
52 Week Range79.11 - 121.53
Volume1,800,205
Avg. Volume6,997,677
Market Cap191.863B
Beta (5Y Monthly)0.79
PE Ratio (TTM)29.28
EPS (TTM)3.71
Earnings DateOct. 28, 2021 - Nov. 01, 2021
Forward Dividend & Yield5.20 (4.86%)
Ex-Dividend DateOct. 14, 2021
1y Target Est127.01
  • Motley Fool

    Could AbbVie's New Collaboration Be a Blockbuster?

    AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment.

  • Motley Fool

    3 High-Yield Dividend Stocks Warren Buffett Loves

    This trio, with yields ranging from 4.7% to 5.4%, should net Berkshire Hathaway over $635 million in annual dividend income.

  • Motley Fool

    Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal

    AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. The deal could be worth up to nearly $1.8 billion including milestone payments. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio.